Pharming Group N.V. (PHAR) Form 6-K — Jul 30, 2026
Pharming Group N.V. reported second quarter 2026 total revenues of $90.2 million, a decrease of 3% compared to the prior year, driven primarily by a 10% decline in RUCONEST revenue to $72.3 million. In response to these results, the company revised its full-year 2026 revenue guidance to a range of $375 million to $395 million, reflecting a $30 million reduction from previous expectations. Despite the overall revenue decline, Joenja revenue demonstrated strong growth, increasing 40% year-over-year to $17.9 million in the second quarter.
Key figures
- Eps
- 0.003
- Revenue
- 90.2 million
- Guidance
- Total revenues between $375.0 million and $395.0 million; Total operating expenses between $315.0 million and $320.0 million
- Net Income
- 1.6 million
- Revenue Yoy
- -3%
- Cash Position
- 159.5 million
- Joenja Q2 Yo Y Change
- +40%
- Joenja Q2 2026 Revenue
- 17.9 million
- RUCONEST Q2 Yo Y Change
- -10%
- RUCONEST Q2 2026 Revenue
- 72.3 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.